Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
Keebler D, Revill P, Braithwaite S, Phillips A, Blaser N, Borquez A, Cambiano V, Ciaranello A, Estill J, Gray R, Hill A, Keiser O, Kessler J, Menzies NA, Nucifora KA, Vizcaya LS, Walker S, Welte A, Easterbrook P, Doherty M, Hirnschall G, Hallett TB. Keebler D, et al. Among authors: easterbrook p. Lancet Glob Health. 2014 Jan;2(1):e35-43. doi: 10.1016/S2214-109X(13)70048-2. Epub 2013 Dec 10. Lancet Glob Health. 2014. PMID: 25104633 Free PMC article.
The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.
Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, Gilson R, Easterbrook P, Matthias R, Scullard G, Johnson MA, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group. Smith CJ, et al. Among authors: easterbrook p. J Infect Dis. 2005 Oct 15;192(8):1387-97. doi: 10.1086/466534. Epub 2005 Sep 14. J Infect Dis. 2005. PMID: 16170756
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.
Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Dunn D, Delpech V, Taylor GP, Walsh JC, Phillips AN; United Kingdom Collaborative HIV Cohort (CHIC) Study Group. Benzie AA, et al. Among authors: easterbrook p. AIDS. 2007 Jul 11;21(11):1423-30. doi: 10.1097/QAD.0b013e3281532ca7. AIDS. 2007. PMID: 17589188
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A; UK Collaborative HIV Cohort Study. Phillips AN, et al. Among authors: easterbrook p. AIDS. 2007 Aug 20;21(13):1717-21. doi: 10.1097/QAD.0b013e32827038bf. AIDS. 2007. PMID: 17690569
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.
Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study. Phillips AN, et al. Among authors: easterbrook p. Lancet. 2007 Dec 8;370(9603):1923-8. doi: 10.1016/S0140-6736(07)61815-7. Lancet. 2007. PMID: 18068516
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study. Bansi LK, et al. Among authors: easterbrook p. AIDS. 2008 Jan 30;22(3):349-56. doi: 10.1097/QAD.0b013e3282f4709a. AIDS. 2008. PMID: 18195561
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.
United Kingdom Collaborative HIV Cohort Study; Lee KJ, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips AN, Sabin CA, Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B, Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C. United Kingdom Collaborative HIV Cohort Study, et al. Among authors: easterbrook p. AIDS. 2008 Oct 1;22(15):1943-50. doi: 10.1097/QAD.0b013e32830e4cf3. AIDS. 2008. PMID: 18784458
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C; UK Collaborative HIV Cohort Study. Bansi L, et al. Among authors: easterbrook p. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):391-6. doi: 10.1097/QAI.0b013e3181ab73cc. J Acquir Immune Defic Syndr. 2009. PMID: 19553826
Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK Collaborative HIV Cohort Study. Bansi L, et al. Among authors: easterbrook p. J Infect Dis. 2009 Sep 1;200(5):710-4. doi: 10.1086/605024. J Infect Dis. 2009. PMID: 19635022
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.
Gilson RJ, Man SL, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C, Pillay D, Schwenk A, Johnson M, Easterbook P, Walsh J, Fisher M, Leen C, Anderson J, Sabin CA; UK Collaborative HIV Cohort Study Group. Gilson RJ, et al. HIV Med. 2010 Feb;11(2):152-60. doi: 10.1111/j.1468-1293.2009.00755.x. Epub 2009 Sep 1. HIV Med. 2010. PMID: 19732175 Free article.
335 results